REGISTERED CHAIUTY NUMBER: 118440S Report of the Trustet4 UnAudlted FlnanelAI Statements For The Yt*r Ended S Aprll 2024 for THE LORNA & VUTI CHERNAJOVSKY BIOMEDICAL RFSEARCH FOUNDATION Hilden Park Accountants Limited Hilden P8rk House 79 Tonbridge Road Hildenborough Tonbrid8e Kent TNII 9BH
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION CoDteDts of the 1¢111 StatenwD¢$ For The YeAr Ended 5 April 2024 Report Df the Trustees Iwdependen¢ Ex•mlD¢r'$ R¢port Stat¢meTrt of FlnantiAI Actiyitiei Statement of FIDnelAI Pojltlon Statement ofc8Jh Flowj Notes to the Stitement of Ciih Flowi Notes to ¢h¢ FlTran¢ll SltemeDt• 10 to 15 DttAlled Stlttrment of Flnell Actlvltl 16 to 17
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION RepDrt of the Trustees For The Year Ended S Aprll 2024 The (rustees present their report with the fjnancial statemenL4 of the charity for the ycar ended 5 April 2024. The trustees hllve adopted rhe provisions of Accouniing and Reporting by Ch&rilleS'. Stement of Recommendcd Practice applicable to charitie5 preparing their accounts in accordance with thc Firbancid Reporting SiandArd applicable in th¢ UK 8nd R¢public of Ireland IFRS 1021 l¢ffe¢tiv¢ l January 20191. OBJECTIVLS AND ACTIVITIES Urwjer the terms of tlie original Trusi Deed. the trnstees have discreiion to promote. advance and support charitirs, charitable OT8anisation$, Charitsble purposcs and ¢haiilable causes includin8 bui noi limited io.. The protertion promotion of the h¢<h of the public by the provision of grants to support biomedicAI rtsearch in the riclds of auroimmunity, inflammaiion, infeciitsus disca5cs and agcillg esp18]IY focussed on ihe development of practical applications in the form of new iargeied tteAunents. The I$¢¢¢S must the income and may use th¢ capithl of the charity in promoling th¢ objectives. The trustees. hAviii8 re8ard to the Publi¢ Benefit Guidance published by the Charity Commission in accordance N%ryth Sectlon 17 of the Charities Act 201 l. consider that the pUryse5 and xtivities of the charity .satisfy the Tcquircmehts of the public benefit iesi s¢¢ ou¢ in section 4 of the same A¢1. The trustees have paid due regard to guidanc¢ issued by the Charity Commission in deciding whai activities the charity should undrrtake. Page I
THE LORNA & VUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Rtport ofthe Trustet5 For The Year Ended S April 2024 ACHIEVEMENT AND PERFORMANCE The Foundation entered an as?reernent in 2021 with Conncct Immune Rucar¢h, a ¢onsortium of national medical r¢search ¢harities comprisin8 primarily of Versus Arthritis, The Muliiplc Sclerosis Society. Juvenile Diab¢tes Research Fund, along with thc Briiish Society for Immunology io fund research inio the common ¢aus¢s ofautoimtnunity. This Targeting shared e¢hanism5 in immune-TMediated inflarnwnatory disea5¢5" Inltiative provides rhe opportunity lo think and research ditrerently in auroimmunity by working across disease areas in the Iranslaiional space. Building on decades of research conduGted tn individual disease 2re2S, it was umely to invest in a cross-dise8sc approach to identify potential new treatments for people living with 8Utoirnmunc conditions. Initially fvnding was offered for 10 pilot Tes¢ar¢h projecis, whi¢h have now been comple*d and final reports received. Expressions of Interest for PhH5c 11 funding more substantial thding to continue the work in the pilot projects were received and 4 selected for full applications. Our partner charities for phase I decided noi to ¢oniinue with their funding. so the Foundation comrnirted to fvnding alone ? research projcct$ for UP to £500.000 each. Decisions will be made in 2024 after expert ¢xternal rcvicw. Th¢ Irustees orB&nised a s¢icntific symposiuffl in July 2023 at Aston University covering & day and a h8lf. Researchers receiving grant5 from the "Targaing Shared mechanisms in immunc-mcdiatcd inflkmmorory diseases initiative presenred Iheir results and plxns for fviure work. and were encoura¥ed lo make pot¢nti31 new collaborations. On second day, all 7 PhD sludenls fundcd by ihc Foundalion PTcscnlcd theif work. The 7 PhD Sludcntships 2rc now in the process of finishinx their studies And writin¥ up towords compl¢tin8 their doctoral Ihe5is. On¢ has already r¢ceiv¢d their do¢torate. Assessment of PTO8res5 has bccn through written reports snd presentations by SUpeIS0rS and smdenls either in person or vha Zoom 8nd at Ihe 5ymw5ium in Bimingham. All were Considered by the Irusiees as progressing saiisfaciorily. The Irus¢ees agrced to fund a maximum of 2 p0st.docraI Fellowships available to currenr PhD students. A call was announecd for applicAlion5. bc dccided upon in 2024. Incoming rcsourGes for thr period amountcd to £487,750 12023.. £588,250). Reseryes will continue to bc m&intained io providc futurc incoTnin8 rc50urccs and awarded as 8Tant5 when hppropri0 charitable instiwiions and causes are identified or when costs become payabl¢. Tlie trustees, overall irtvestmerti objective as stated in the investment managemeni Agreemeni is io maintain a multi-assei portfolio and achi¢v¢ a balan¢e of in¢ome and capilal ¥ro. The charity operRte5 ethical investment policy. The perfomiance of ihe ¢ru$t tnve$tment porrfolio is considered at regular intejvals Wlth the inVCSlmeni managcr and is bcnchmarked igainst vaTiQU5 market indicc5 (including Ihc FTSE WMA Sio¢k Market Balanced Indexl to ensure the fund5 hcld are PCTforniin8 well. This manager, which is re8ulated by the Financial Conduct Authoriry in the United Kingdom, manages the inveslmenis within the restrictions sel oul in the inveslmcnt managcmcnt $8rcement. Any issues ore addressed wilh the trustees a5 and when they arise. The trustees were satisfied with the p¢rform2nce of the invesknents during ihe period. Investments at the period end had a market Value of £1.712.72212023.. £1.564.2211. It is the trustees, policy noi io relain rest¢$ as ihe ¢hari¢y's overheads are low. FUTURE PLANS During the coming 2023124 financial year thc tru5tccs plan to continuc 5UPPOTNng the "Targeting shared mechani5m5 i immune-mediaied inflammatory diseases. initiativ¢ by fimding two Phase 11 projects for up to £500.000 each. The Foundation wlll con(ittue support the PhD projects awarded from the firll call until ¢omplerion, and award up to 2 POs&41ocLora] F¢llow5hips. The tru5tecs will reviewthc5r portfolio and dccidc upon thc focu5 of thcir next fUrlg programmc. Pag¢ 2
THE LORNA & VUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Report of the Trustees For The Year Ended S April 2024 STRUCTURE. GOVERNANCE AND MANAGEMENT GoverDing dotument The charity IS ¢Olltrolled by its governin8 documenL a deed of tnisi and constiiuies an unin¢orporatrd charity. R15k m&ngemenl Th¢ tVU5tees have a duty to identify and Teview the risk5 to wthi¢h the charity is exposed and to ensure appropriate controls are in place 10 Provide reasonable assurance again frad 2nd error. The charity is an unin¢orporat¢d r¢gistered charity. constructed under a Trust Deed dated 9 July 2019. Th¢ trustees hold the capital and Income of the Charity's Twst Fut)d upon irusl to apply th¢ in¢ome and. a5 far as may be necessary. the capital for the purpts5¢5 set out in clause 2.2 ofthe Trust DECd. The minimum number ofirnstees required by the Tru Deed is 3 afid the maximurn 15 5. Future injstees must be appointed by resolution of thc trustcrs and musi hold offi¢e for at least Ihrtt y¢ars from the date of their appointsnent. As required by Ihe Trusi Deed, Ihe ITUStees meet iio less than twicc a ycar. Except where herwiSe provided. every issue may bc dctemined by a simplt majority of volcs cast at a mttting of Ihc Iru5tces bul a re501ulion which is wriiiD8 and signed by all ihe trustees 15 95 valid as a resoluiion possed At a meeting. For this purpoK, th¢ r¢solution may bc contained in more than one document nd will bc treated as passed followt)8 receipi of the nece55ary written approval. Every (ntee has one vote on each issue. In thc event of a tic. the chimvan shall have the d¢ciding vol¢. The Iru$ie¢s have not adopted ary policies or pro¢¢dures for the induetion and trdinin8 of trustees. When m&king decisions. the trustees &ssess the risks 10 wthi¢h ihe CrItY mighi be exposed. Thc trusiees Cary out due-diligence oji charilablc institutions bcfore 8ran15 arc made and do¢umen¢ 411 major decisions. As part of thc granl-making proccss. Ilie Irustees asree io follow up with Ihe donee io Cnsure ¢hAi fvnd5 have been applied foi. the agrccd purpose. This ¢ould b¢ by way of a pro8r¢55 report, Personal REFERENCE AND ADMINISTIL4TIVE DETAILS Regljtered Chsrlty number 11 $4405 Prlnelpal #ddress P.O.Box 1198 Whitstable Kent r5 9DW Truste Dr Loma Chernajovsky Profcssor Yuti Chernajov5ky Professor Paul-Peter Tak Independent Examln¢r Hilden Park Accountants Limiied Hilden Park House 79 Tonbridge Road Hildenborough Tonbtidge Kent TNI19BH Pag¢ 3
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Report of the Trnstees For The Yegr ElldÉd S April 2024 REVERENCE A]¥D ADMINISTRATIVE DETAIIS InvestmeTrt idvi50r$ and baRkeTS Coutts & Co 440 Strand London WC2R OQS Septwnber 3. 2024 Approved by order of the board of trwstees on............................................. and signed on it5 bchalf by.. Professor Yuti Chem&jovsky- Trustee Page 4
IndepEnd¢nt Examiner's Report to the Trnste¢s of The & Yuil Chernajovsky Biomedlcal ReBeareh Foundation Ihdependent ex*mlntr'8 rtport to the trugttes ofThe L•rn8 & Yy¢i Ch¢Tn&lov8ky Blomedleal I rrrM)rL to the charity trustees on my examination of the ar¢ounts of The Loma & YuLi Chemajovsky Biomedical {le Trnst) for the year ended 5th April 2022. Respon51bilitla and b%5i5 of report AS the charity trustees of the Trust you are re5ponsiblc for the preparation of ihe accounts in a¢¢oTdance wth the requiremcnts of the Charities Act 2011 I'¢h¢ A¢YI. report in respect ofmy examill2tion of the Trusvs Carried ouc under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by thc Cliarity Commi55ion under section 14515llbl of tht Act. An indcpendent cxamination does not involve 8aihcrin¥ all the tvidence that would be required in an audit and consequently does not cov¢r 811 th¢ mRtters ihat an 8uditor ¢onsiders in giving their opinion on the accounts. The planning and conduct ol- an audit gocs beyond the limitcd assurance that indendenC examination can provide. Con5equEntly. l express no opinion a5 to whether ihe accounts preseTht a 'true and fair, view and my report is limired ¢0 thos¢ 5pecifsc matters set out in the Independent ¢xamin¢r'$ 5ta¢em¢nt. lttdepeTrdtni ei#mlner'5 Slattment Since your charity's gr055 incomc excceded £250.000 your examlner must be a memkr of & lisred body. T can confim that I am qualified to undertake the examination becauje l am a Te8i&tered memhcr of Associaiion of Chartered Certificd Accountants which is one of ihe listed bodies. I havc completed my exAminaiion. I ctsnfirrn that no maierial matters have come to my attention in connection with the cxamination 8ivinK mc cause lo bcli¢v¢ that in any matcrial re5PCCt'. l. a¢couniing rordS were noi kew in respect of ihe Trust as required by section 130 of th¢ A¢ or 2. Ihe a¢¢ounts do noi accord with Ihose records; or 3. Ihe a¢count$ do not comply with the applicable requirements ¢on¢erning the farm and ¢Dnwnt of aceounts set out in the Charitics (Accounts and Rcports) Regulations 2008 other than any rcquircment thai the Accounts give o true and fair vicw which ij not B m4¢ter considered as Part of an independent ¢x4minatLQn. I hawe no ¢vn¢erns And hawe rome across no other matters itt Goniie¢tion wilh the examinaiion to which attention should bc draw) in this report in order io enable a proper undcrsianding of the accounts to be reached. Andrew Appleion FCCA Hilden Park Accountants Limited Hilden Park House 79 Tonbridgc Road Hildcnborough Tonbridge Kcnt TNII gBH Date.. Page 5
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Statem¢Trt of Financial Activitit5 Ftsr The Year Ended S April 2024 2024 Unwestritted nd 2023 Total funds Noies INCOME AND ENDOWMENTS FROM Investment income Other income 66.904 420046 40.448 547.802 TDtal 487,750 588,250 EXPENDITURE ON Raising fvnds 3.786 12,840 Ch8rltabl¢ 8CtlvltleJ General 8rants 48,507 36,000 Other 14.087 115,200) Tot#1 66JBII 33.640 Net gainslllosseBI on investments 119,791 1136,513) NET IIYCOME 418.097 RECONCILIATION OF FUNDS To¢al funds broughi forward 2J61 J59 1.943,262 TOTAL FUNDS CARRIED FORWARD 2,9112521J 2,361,359 The notes form part of the5c finanrial 5tateMer Page 6
THE LORNA & VUTI CHERf4AJOVSKY BIOMEDICAL RESEARCH FOUNDATION Siaternent of Flngnelal PositiOD S April 2024 21124 Total funds 2023 Total fund5 Notes FIXED ASSETS Invesimcnts 10 1,712,722 1,564.221 CURRENT ASSETS tkbiors Ctsh at bank 41.002 1288,404 82,399 1.499.419 I J29,406 1,581,818 CREDITORS Amounts falliiig due within one year 12 (139.61K8) 1784.680) NET CURRENT ASSETS .189.798 797,138 TOT AL ASSETS LESS CURRENT LIABILITIES 2,902J20 2.361.359 NET ASSETS 2,902J20 2,361.359 FUNDS Unresiri¢ied fvnds 2,902,520 2,361,359 TOTAL FUNDS 2,902,520 2.361.359 The financial Stsicments were approved by thE Board of Trusiees and oulhorised for issue on and wrre sigrttd on its behalf by.. Yuti Chern&iovsky- TrNstee The not¢5 forn part of thrsc financial statements Page 7
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Stalement of Ca$h Flows For Tht Ye•r Eoded 5 April 2024 1024 2023 Not¢5 Cash IIow5 from optr¥iing actfvities Cash generated from oper8tions {203268) 27.948 Net cash {u5ed inllprovided by opcr2ting activitie5 {203 3681 27.948 Cish flows from Investlng ictlyltl Purchase of fixed assei inwcsimrnls Sale of fixed asset investments Interest received Dividends received IJ,060,293) 1.113l,634 19,434 1.47B 11,087,877) 1.086.370 7.466 1.888 Net cash (used inllprovided by investin8 activities (7.7471 7.847 ChAnEe In eajh and cash tqulvaltnt$ In the reportlng perlod CI5h And cAsh equlv8lentS At the btglnnlng of the rtportlng ptrlod 1211.015) 35,795 IA99h19 1,463,624 C8ih gnd cash equlv*lents at the tnd of th¢ r¢por¢ing p¢rlod 1388,404 1,499,419 The notes form part of these finartcial statements Page 8
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Nott5 to the Statement of Cash Flow5 For The Yer Ended 5 April 2024 RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES 2024 2023 Net income for the r¢porting periodlgs per the Statement of Finthtl*l Activltlts) AdJu$tments for: (Gainlllosses on inv¢siments Illre5t received Dividends received Decreasc/lincre&scI in d¢btOTS Decr¢ose in Creditors 541.161 418,097 {119.842) 119.4341 (1.4781 41 J97 (645.0721 135.373 17,466) 11,8881 15,2761 1510.8921 Ntt ¢a5h (used Inyprovlded by optrAtIoAs 1203,268) 27.948 ANALYSIS OF CHANGES IN NET FUNDS Ai 6.4.23 Cash flow At 5.&24 Net C95h Cash ai bank ,499,419 1211.OlSI 1.288A04 1.499.419 1211,0151 1,288A04 Ttstal 1.499.419 1211,015) 1288,4114 Thc note5 form part of the5r financial statemeE)ts Page 9
THE LORNA & YUTI CHERNAJOVSKV BIOMEDICAL RESEARCH FOUNDA TJOTrI P4otr5 to the FIAan¢ial Stotements For The Ye8r End¢d 5 April 2024 ACCOUNTING POLICIES Ba51s of prepxrlthg the finantial stitements The financial 5tatcrnents of thc charity. which is a public benefit entity under FRS 102, have been prepared in accordance wth the Charities SORP IFRS 102}'Aecounling and Reportin¥ by Chaii¢ies-, Siat¢meni of Recomrnended Practi¢e applicable io ¢hariii¢s preparing their accounts in accordance with the Financial ReportinR Standard applicable in the UK and Republic of Ireland IFRS 1021 l¢ff¢ciive l January 20191., Financial Reporting Siandard 102 'The Financial Reportin# Standard applicable in the UK and Rcpublic of Ireland, and Ilie ChaTltie5 Act 20 11. Thc financial s121em¢nis have b¢¢n pr¢p4red und¢r Lh¢ historical c05t convention, with the exception ol inv¢stmenis which are included at markd value. as modified by the revalu*ion of certain assets. The financial ststements dre presented in pounds Sterling and round¢d to the nearest pound. IDtome All income 15 re¢ognis¢d in ¢he Statemenl of Financial Actyvities once the charity hLS cntitlemeni to ihe fiJnd5. It 15 probèble that the income w411 be received and ihe amount cin be m¢&suT¢d r¢liably. Invcstmcnt income is reco8nised whcn it 15 reccivablc. Other income relates lo royalties and is r¢cogni5¢d in th¢ period to which it relate5. ExpendItre Liabiliiies are recogniscd as cxpcndilurc 85 SL)on as there is & legal or cons¢ructiv¢ obligation cornmittin¥ the charity to that expenditure. it is probable thai a Iransler of economic benefits will be required in settl¢men¢ und the amount of the obligation can be measurcd reliably. ExpendiluT¢ is aOUn1¢d for on an (ru&15 basis and has been ¢IsIfIed und¢r headings tha¢ aggregate all cosi related to the cate80ry. The charity h85 une charilabl¢ 4¢livity io whi¢h di¢ and support CUS re allocated. Governance ¢osi$ in¢lude all those asso¢iaied with consiiiutionol ond statutory requirement includin8 thc preparation, and indepcndent cxarnination, of thc 51atutory accounts, and Icgal and prof¢sstonal fees. Grant5 payable ar¢ ¢haTg¢d in the year wh¢n ¢he offer is mad¢ exc¢p¢ in those c&5e5 where the off¢r 18 conditional, such grants being recognised as expendiiure Mthen the condiiions attnching are fuifllled. Grants offered subject to condiiions which have noi brell at ihe year end are noted as a commitmenL but not a¢¢rued a5 exp¢ndilure. TxxAtlon The ¢harity 15 excmpt from thx ort its ch&ritablE activitlES. Fund aecountlng The Charity has an urtres¢ricted fijnd created by the assignment of Toyalties and ihe income of the Trust is unrestricted. The lernis of the Trust allow the capital of th¢ fund to be 5p¢nt if the Trustees so detcrmine. UnrestTiCtcd incomc comprises fi]nd5 which the trustees are frtt to Usc for any purpose in fvrtherance of the charitable objects. Unr¢sMcted fvnds include deSinted funds where rhe trustees, at th¢ir discretion, have creaied 8 nd for a specific purpose. Forelgn crrentle5 Assets and liabilities in foreign CUTrencics (ran51ated into stCTling at the Tales of exchllnge ruling at the statement of financial position date. Tr8nsac¢ions in foreign CLtrrencies arr translated into sterling at the rate of exchange ruling at the date of tranlIOn. Exchange differences ar¢ taken into &c¢ouni in arriving ai the OP¢Tating re5uIt. Pa8e 10 contirtued..
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATIOPI Notes to the Financial Statements- CODtinued For The Ye8r Ended S April 2024 ACCOUF4Tll¥C POLICIES - CQDtlnued Investments Fixed asset investmwts are a forni of financial instnmient and are initially recognised at their transaction cost and subsequently measured at fair value 8t the Balance sh¢ei datc, unless the value cannot be meaqured reliably in which case it is mea8ured at cost less irnpairnienl. Investment gains and losses, whether rcaliscd or unrealised, arc cornbined and pre8¢nted a&'Gain{LO$8es) on investsnents, in th¢ Stot¢m¢nt of financial activities. Finaneial in$truments' Financial instruments are classified and a¢count¢d for a¢cording to the substance of the contracDJal agreement as financial assets or financial liabilities. Golng conccrn Afiei TnakiT]g the iieeesgary enquirie5, the ttwtees have a reasonable expectBtion that ihe Charity ha8 adequat¢ reserv¢s lo ¢onlinue in existence for the foreseeable fi]ture and there are no material uncertainties regarding 8oin8 concern. On this ba8is the Charity continues 10 8dopt the going concern ba818 in preparing its fit]an¢ial sthtements INVESTMENT IIYCOME 2024 2023 UK iniere8t & dividends Overseas intera$t & dividend8 UK bank intere81 1,47B 45,992 19,434 1,887 31.094 7,467 60,904 40,448 OTHER INCOME 2024 2023 Royalties from YEDA 420.846 547,802 By a Deed of A%signment dated 14 Au8USt 2019 royalties due to Yuii Chtrnajovbky w¢r¢ foTmally agsi¥ned to the Trustees until fvrther nouce. Pagell ontinued...
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUT4DATJOP4 Note5 to the Flnlntial StAttments- eontlnued For The Year Ended S Aprll 2024 RAISING FUNDS Investment mAn#gemtTht tosts 2024 20?3 Portfolio managcmen( 3.786 CHARITABLE ACTIVITIES COSTS Grant fi]nding of Direct Costs Isee noi¢ 6) (See note 71 Toials General gronts 20A14 28,1193 48.507 DIRECosTs OF CHARITABLE ACTIVITIES 21124 2023 Research meeLin8 Costs 20,414 G114NTS PAYABLE 2024 2023 General 8rnnt8 28,1193 36,000 The Charity has made ihe following grants to institutions durin8 thc year.. 2024 2023 Brjtish Society for Rescafch on A8ein British Society for Immunology Williarn Harvey Resear¢h Foundation oiher grants Unused grarts reveT5cd in the yc 1&1102 15,000 15001 182 12,892) 21.0(10 28,1193 36.000 Page 12 continued...
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Notes to the Financial Statement5- Colltlnued For The Year EDd¢d 5 April 2024 SUPPORT COSTS Governance costs Finance Other Totals Other TC50urce5 expended 1.686 5,981 6,4211 14,087 Support cosw included in the above, are 25 follows= 2024 Oiher rt50urces expended 2023 Total a¢tivities Bk charges Profit or loss on foreign exchang¢ Administrative c05t5 Ar¢ounlancy fees Independeiit Exdminers fees 1,686 3,921 2,060 3.420 3.000 1,345 127.551) 1,826 6.3011 14,087 {15200) TRUSTEES, REMUNE114TION AiYD BENEFIT5 There were no tru5tee5' rernuneration or other benefiis for th¢ year ¢nded 5 Aptil 2024 nor for the ycar endcd 5 April 2023. Tru5teeJ expense There were no tTU5tees' expcnscs paid foi. the yeor end¢d 5 April 2024 nor for the year ended 5 April 2023, io. FIXED ASSET INVESTMENTS Li5tcd investmcnis MARKETVALUE At 6 April 2023 Additions Disposa15 Revaluatiohs l J64321 1.060,293 (1,031.634) 119,842 At 5 April 2024 .712,722 NET BOOK VALUK At 5 April 2024 1,712.722 Ai 5 April 2023 1.5642?1 Fixed asset investments comprise UK fix¢d interest securities of £843.49412023.' £941,851), UK quoted equities of £254,147 12023.. £233.4551. OVCT5cas eqUltie5 of £570,595 12023.. £388,9IS) and Commodities £44,486 {2023: £Nill. Po8¢ 13 ntinued...
THE LORNA & VUTI CHEI(NAJOVSKY BIOMEDICAL RESEARCH FOUNDA TION Note5 to the FinqneiAI Ststements- eontlnued For The Ytor Ended 5 Aprhl 2024 FIXED ASSET INVLSTMENTS- contffinued Cost or valuation at 5 April 2024 is represented by.. L15ted Investrnents Valuation in 2022 C05t 148,501 1.S64.221 .712.722 DEBTORS: AMOUNTS FALLINC DUE WITHIN ONE YEAR 2024 2023 Prepayments and aecNed income 41.002 82.399 12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2024 2023 Other creditor5 Accrued expcn5eS Acerua15 for 8rants payable 20 6,420 133,168 20 6.180 778,480 139.608 784,680 Movemcnl of accruals for 8Tants payablc.. 2024 2023 At 6 April 2023 Gra[ approvEd Unused 8rants revtrscd in (he ycar Grani paymenrs in th¢ year 778.480 30,984 (2,892) {673,404) 1,289,732 21.000 1532,2521 At S April 2024 133,168 778,480 Page 14 continued...
THE LORNA & YUTI CHERNAJOVSKY BIOMEDICAL RESEARCH FOUNDATION Notej to the Fl•8nrl81 Statements- foDOnued For The Yt#r Ended 5 Aprll 2024 13. RELATED PARTY DISCLOSURFS There were no related party transliOnS for the year ended 5 April 2024. PAge 15